<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03003000</url>
  </required_header>
  <id_info>
    <org_study_id>1335.5</org_study_id>
    <secondary_id>2016-000902-12</secondary_id>
    <nct_id>NCT03003000</nct_id>
  </id_info>
  <brief_title>Ibuprofen/Caffeine Lower Back or Neck Pain Study</brief_title>
  <official_title>A Randomized, Placebo- and Active-controlled Multi-country, Multi-centre Parallel Group Study to Evaluate the Efficacy and Safety of a Fixed Dose Combination of 400 mg Ibuprofen and 100 mg Caffeine Compared to Ibuprofen 400 mg and Placebo in Patients With Acute Lower Back or Neck Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of a 400 mg ibuprofen/100 mg caffeine tablet in comparison
      to a 400 mg ibuprofen tablet for the treatment of acute lower back or neck pain. To assess
      the safety and tolerability of a 400 mg ibuprofen/100 mg caffeine tablet in comparison to a
      400 mg ibuprofen tablet and a placebo tablet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2016</start_date>
  <completion_date type="Actual">September 28, 2017</completion_date>
  <primary_completion_date type="Actual">September 24, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain On Movement (POM) with regard to the Worst Procedure (WP), i.e. the procedure with the highest pain score at baseline (POMWP), between baseline (Day 1 morning pre-dosing) and Day 2 morning, 2 hours after drug intake.</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for POMWP (Pain on Movement, worst pain) between baseline and the morning of Day 6 (POMWPAUC120h).</measure>
    <time_frame>Baseline and Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pressure Algometry (PA) between baseline and Day 2 morning, 2 hours after drug intake.</measure>
    <time_frame>Baseline and Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4-point verbal rating scale of efficacy by the patient at the end of treatment (0 = poor, 1 = fair, 2 = good, 3 = very good)</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a decrease in POMWP (Pain on Movement, worst pain) of at least 30% between baseline and Day 2 morning, 2 hours after drug intake.</measure>
    <time_frame>Baseline and Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a decrease in POMWP (Pain on Movement, worst pain) of at least 50% between baseline and Day 2 morning, 2 hours after drug intake.</measure>
    <time_frame>Baseline and Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first meaningful POMWP (Pain on Movement, worst pain) relief within 2 hours after the first dose of study medication.</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for POMWP (Pain on Movement, worst pain) between baseline and the morning of Day 4 (POMWPAUC72h).</measure>
    <time_frame>Baseline and Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">635</enrollment>
  <condition>Back Pain</condition>
  <condition>Neck Pain</condition>
  <arm_group>
    <arm_group_label>ibuprofen + caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Dose Combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen</intervention_name>
    <arm_group_label>ibuprofen + caffeine</arm_group_label>
    <arm_group_label>ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <arm_group_label>ibuprofen + caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed and dated written informed consent at Visit 1 in accordance with Good Clinical
             Practice (GCP) and local legislation.

          -  Male or female patients who are &gt;=18 years with current diagnosis of acute back pain
             or of neck pain for at least 24 hours, but less than 21 days.

          -  Acute back pain or acute neck pain resulting in Pain on Movement (POM) &gt;=5 on the 0-10
             Numerical Rating Scale (NRS) for at least one POM procedure out of 5 standardised
             procedures.

          -  Sensitivity to algometric pressure on the painful trigger point &lt;= 25 N/cmÂ².

          -  Women of childbearing potential must be ready and able to use highly effective methods
             of birth control.

          -  Reliable, cooperative, and of adequate intelligence to record the requested
             information on the analgesic questionnaires.

          -  Examined by the attending physician and medically cleared to participate in the study

          -  In good general health, with a body mass index (BMI) &lt; 30, and have no
             contraindications to any of the study medication

        Exclusion criteria:

          -  History of 3 or more episodes of back or neck pain in the last 6 months excluding the
             current episode.

          -  Patients with pain at rest &gt;= 9

          -  Patient with chronic back or neck pain as defined as pain for 3 weeks or longer.

          -  Back or neck pain that is attributable to any identifiable cause (eg. disc prolapse,
             spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological
             diseases or tumour)

          -  Any strains of the back or neck muscles documented by clinical evaluation and
             anamnesis that occurred 21 days to 3 months prior to the screening visit.

          -  Surgery due to back or neck pain or rehabilitation due to back or neck pain in the
             last 12 months.

          -  Prior use within the last 3 days before Visit 1 or concomitant use of any anti-
             inflammatory drugs, heparinoids, muscle relaxants or analgesics (including but not
             limited to short-acting glucocorticoids, non-steroidal anti-inflammatory drugs
             [NSAIDs], herbal preparations) for the same indication or other indications.

          -  Spinal injections should have been discontinued in due time (investigator's judgment)
             before patient enrollment to allow complete wash-out of the active ingredient based on
             investigator's judgment.

          -  Known severe hepatocellular insufficiency, severe renal insufficiency or Gilbert's
             syndrome (Morbus Meulengracht)

          -  Patients taking Central Nervous System (CNS) or other psychotropic drugs, or any
             nutritional supplement known to have psychotropic effects such as St. John's Wort,
             Chapparal, Comfrey, Germander, Gin Bu Huan, Kava, Pennyroyal Skullcap, or Valerian
             within two months of taking the first dose of study medication. Patients who have been
             on stable doses of these medications for at least two months will be allowed into the
             study, as long as they maintain this dose throughout the study, and their condition is
             judged stable by the Principal Investigator

          -  Any other medical condition that would interfere with efficacy and safety assessments
             based on investigator's judgment or any on-going clinical condition that would
             jeopardize patient's or site personnel's safety or study compliance based on
             investigator judgment

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr. Steinebach, Essen</name>
      <address>
        <city>Essen</city>
        <zip>45277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Schaefer, 45355 Essen</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum BocholderstraÃe</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unterfrintroper Hausarztzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Pabst, Gilching</name>
      <address>
        <city>Gilching</city>
        <zip>82205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Kai Gastl</name>
      <address>
        <city>Gilching</city>
        <zip>82205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>medicoKIT GmbH</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Dr. Martz</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Dahmen, 22415 Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Chevts, 76199 Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DÃ¼nnwaldpraxis, KÃ¶ln</name>
      <address>
        <city>KÃ¶ln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Klein, KÃ¼nzing</name>
      <address>
        <city>KÃ¼nzing</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnÃ¤sthesiologie Rheinbach</name>
      <address>
        <city>Rheinbach</city>
        <zip>53359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Sauter</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie und Psychiatrie / Psychotherapie</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution, City Out-Patient's Clinic #109</name>
      <address>
        <city>St. Petersburg</city>
        <zip>192283</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre &quot;Reavita Med SPb&quot; LLC</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194325</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Outpatient dep.no.107;clinc.pharmacology,st.petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195030</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>December 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2016</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Neck Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

